safranal has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akagawa, M; Ishii, M; Ishii, T; Kai, K; Maeda, A | 1 |
| Hazman, Ö; Ovalı, S | 1 |
2 other study(ies) available for safranal and Insulin Resistance
| Article | Year |
|---|---|
Safranal, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves glucose tolerance in diabetic KK-Ay mice.
Topics: Animals; Crocus; Cyclohexenes; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred Strains; Muscle Fibers, Skeletal; Myoblasts; Plant Extracts; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Signal Transduction; Terpenes | 2014 |
Investigation of the anti-inflammatory effects of safranal on high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cyclohexenes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Inflammation; Insulin Resistance; Interferon-gamma; Interleukin-1beta; Interleukin-6; Male; Obesity; Oxidative Stress; Pancreas; Rats; Rats, Wistar; Streptozocin; Terpenes; Tumor Necrosis Factor-alpha; Weight Gain | 2015 |